ASYMCHEM LABORATORIES (TIANJIN) CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 76.86 CNY | -0.59% |
|
-1.98% | -33.80% |
| Sales 2024 * | 6.44B 888M | Sales 2025 * | 7.99B 1.1B | Capitalization | 28.33B 3.91B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.42B 196M | Net income 2025 * | 1.87B 258M | EV / Sales 2024 * | 3.18 x |
| Net cash position 2024 * | 7.85B 1.08B | Net cash position 2025 * | 8.22B 1.13B | EV / Sales 2025 * | 2.52 x |
| P/E ratio 2024 * |
19.8
x | P/E ratio 2025 * |
15
x | Employees | 9,788 |
| Yield 2024 * |
0.96% | Yield 2025 * |
1.21% | Free-Float | 60.56% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | -0.59% | ||
| 1 week | -1.98% | ||
| Current month | -10.67% | ||
| 1 month | -17.63% | ||
| 3 months | -21.81% | ||
| 6 months | -48.86% | ||
| Current year | -33.80% |
1 week
74.91
79.17
1 month
74.9192.50
Current year
74.91116.22
1 year
74.91165.27
3 years
74.91380.35
5 years
59.54380.35
10 years
13.09380.35
| Managers | Title | Age | Since |
|---|---|---|---|
Rui Yang
CEO | Chief Executive Officer | 47 | 99-03-31 |
Hao Hong
CEO | Chief Executive Officer | 68 | 98-10-06 |
Elut Hsu
PSD | President | - | 96-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hao Hong
CEO | Chief Executive Officer | 68 | 98-10-06 |
Rui Yang
CEO | Chief Executive Officer | 47 | 99-03-31 |
Xin Yi Hou
BRD | Director/Board Member | 64 | Feb. 28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.88% | 2 M€ | -18.13% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 76.86 | -0.59% | 4,461,081 |
| 24-04-24 | 77.32 | +0.18% | 5,108,832 |
| 24-04-23 | 77.18 | +0.53% | 4,731,064 |
| 24-04-22 | 76.77 | +0.22% | 4,147,116 |
| 24-04-19 | 76.6 | -2.31% | 4,854,712 |
End-of-day quote Shenzhen S.E., April 24, 2024
More quotes
Asymchem Laboratories (Tian Jin) Co Ltd is a China-based company mainly engaged in the contract development manufacturing organization (CDMO) of drugs. The Company's main businesses are the process development, amplification and commercialization of chemical drugs. The Company's product categories cover peptides, oligonucleotides, monoclonal antibodies, antibody-conjugated drugs and messenger RNA. The Company is also engaged in the provision of pharmaceutical formulation solutions, biosynthetic solutions and clinical solutions.
Sector
Pharmaceuticals
Calendar
2024-08-14
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
76.86
CNY
Average target price
112.1
CNY
Spread / Average Target
+45.91%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -33.80% | 3.71B | |
| +25.64% | 653B | |
| +26.37% | 556B | |
| -6.52% | 354B | |
| +20.38% | 331B | |
| +4.52% | 296B | |
| +12.87% | 233B | |
| +5.48% | 201B | |
| -9.49% | 193B | |
| -6.05% | 144B |
- Stock Market
- Equities
- 002821 Stock
